In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Kairos Pharma, Ltd., with a price target of $12.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Joseph Pantginis has given his Buy rating due to a combination of factors related to Kairos Pharma’s ongoing clinical developments and financial position. The company is advancing its lead asset, ENV-105, through Phase 1 and Phase 2 clinical trials for mCRPC and NSCLC, respectively, with significant data readouts expected in 2025. These upcoming clinical milestones, particularly the interim Phase 2 efficacy data for mCRPC anticipated in the third quarter of 2025, are seen as potential de-risking events that could positively impact investor sentiment.
Additionally, the recent positive safety update from the Phase 2 study of ENV-105 in mCRPC patients has reinforced confidence in the drug’s tolerability and safety profile. The absence of dose-limiting toxicities and manageable side effects, coupled with the strategic enrollment of patients at renowned medical centers, positions the company well for future regulatory discussions and potential pivotal studies. These elements collectively underpin Pantginis’s optimistic outlook on Kairos Pharma’s stock.
Pantginis covers the Healthcare sector, focusing on stocks such as aTyr Pharma, Capricor Therapeutics, and Krystal Biotech. According to TipRanks, Pantginis has an average return of -14.3% and a 33.67% success rate on recommended stocks.